EdgeTestMarket TodayOptions TodayIPO
Start free

BLISSGVSBliss GVS Pharma Limited

Rs 623.35▼ -3.01%
Market closedEquity EOD 23 Oct
Compare
52-week rangeThe lowest and highest prices the stock traded at over the last year, from each day's intraday low and high. The marker is today's close: 0% means it sits at the year's low, 100% at the high. It describes where the price is, not where it is going.81.3% up the range
Rs 118Rs 740
BLISSGVS price
Daily candles, adjusted for splits and bonus issues so a corporate action does not show as a crash. Pick a window from one month to the full history, add indicators, or open it full screen.
EOD 23 Oct
IndicatorsVolume

Loading BLISSGVS price...

At a glance
Each figure is shown against the company's sector (the track: the dot is this company, the tick is the sector middle) and, where we hold the yearly filings, against its own recent years (the small trend line).
Market capWhat the whole company is worth on the stock market today: share price times the number of shares. It measures size, not quality.
Rs 6,611 cr
Larger than 57% of 110 peers
sector middle Rs 4,318 cr
P/EPrice to earnings: how many rupees investors pay for each rupee of profit the company made over the last twelve months. Compare it with similar companies rather than reading it alone.
49.4x
Higher than 75% of 93 peers
sector middle 34.9x
Price to bookPrice to book: the share price divided by the shareholders' money per share in the latest balance sheet. Around 1 means the market values the company close to its book value.
5.5x
Higher than 72% of 107 peers
sector middle 3.8x
ROEReturn on equity: the year's profit as a percentage of the shareholders' money in the business. It shows how much the company earns on what its owners have put in.
11.5%
Around the middle of 101 peers
sector middle 11.8%
FY23 8.1%FY26 10.9%
ROCEReturn on capital employed: operating profit as a percentage of all the long-term money in the business, owners' and lenders'. It shows how well the company uses its capital, whatever the mix of debt.
16.0%
Higher than 63% of 105 peers
sector middle 14.9%
FY23 12.1%FY26 16.0%
Debt to equityBorrowings divided by shareholders' money. 0 means no borrowings; 1 means it owes as much as its owners have put in. Not shown for banks and lenders, whose borrowing is their business.
0.00
Under 0.01
sector middle 0.19
FY23 0.11FY26 0.00
Dividend yieldDividends paid over the last year as a percentage of the company's market value: roughly what Rs 100 of shares paid out in cash.
0.2%
Around the middle of 109 peers
sector middle 0.1%
Sales growthHow much the latest quarter's sales grew against the same quarter a year earlier.
+37.6%
Higher than 85% of 102 peers
sector middle +17.7%
FY24 8.4%FY26 14.5%

Peers are the listed companies in the exchange's own industry group: Pharmaceuticals. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.

What the numbers say
Short lines written by fixed rules from the company's own filings and shareholding. A line appears only when the figures cross the rule (for example sales growing three years running), and each names the numbers behind it. Nothing here is a view on whether to own the share.

Latest quarterIn the quarter to June 2026, sales rose 37.6% from a year earlier to Rs 286 cr and profit rose 15.8% to Rs 51.4 cr.

Going well
  • Sales grew 3 years running (Rs 710 cr in FY23 to Rs 927 cr in FY26).
  • Profit grew 3 years running (Rs 73.9 cr in FY23 to Rs 135 cr in FY26).
  • Debt to equity fell 3 years running (0.11 to 0.00).
  • Cash from operations was at least the reported profit in each of FY24, FY25, FY26.

Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.

How the share moved on results
For each quarterly result we hold: the change from the share's close on the last trading day before the filing to its close on the first trading day after it. Results can land during market hours or after the close, and this window covers both. It shows what happened, not what will happen next time.

Over the last 19 results, the share rose on 9 and fell on 10, and moved by 3% or more on 13.

Q4 FY22Q4 FY23Q4 FY24Q4 FY25Q4 FY26

Q4 FY26: results filed 12 May 2026. The share went from its close on 11 May 2026 to its close on 13 May 2026 +2.72%.

Where every Rs 100 of sales goes
From the company's own yearly results. Each year is scaled to that year's sales, so you compare shares, not size: how much went on running costs, depreciation, interest and tax, and how much was left as profit.
4 financial years
Sales, last 12 months
Rs 1,005 Cr
Profit, last 12 months
Rs 142 Cr
Earnings per share
Rs 12.6
Profit growth (qtr, YoY)
+15.80%

Of every Rs 100 of sales in FY26, Rs 84 went on running costs, Rs 3.6 on depreciation, Rs 1.3 on interest and Rs 5.9 on tax; Rs 15 was left as profit.

FY23
86
10
FY24
80
11
FY25
84
11
FY26
84
15
Sales (Rs 100)Other incomeRunning costsDepreciationInterestTaxProfitOther items

Thin bar: money in (sales plus other income). Thick bar: where it went. Each year is scaled to its own sales, so the bars compare shares, not size.

How fast it has grown
Compound growth per year in sales, profit and earnings per share between financial years, from the company's own results. A span appears only if our filings cover both ends of it.
Sales
3 yrs
+9.3%/yr
Latest qtr
+37.6%
Profit
3 yrs
+22.2%/yr
Latest qtr
+15.8%

Per year, compounded, between financial years FY26 and the year named; only spans our filings cover. The faint bar is the latest quarter against the same quarter a year earlier. Earnings per share is not shown: filed figures are not adjusted for bonus issues and splits, so its growth would mislead.

Health check, year by year
Margins, returns, debt and interest cover for each financial year. Each row is coloured against this company's own usual level, so you see what is improving and what is slipping.
MeasureFY23FY24FY25FY26
Sales growthSales against the previous financial year.-8.4%5.1%14.5%
Operating marginProfit from operations, before depreciation, interest and tax, per Rs 100 of sales.13.7%19.6%15.6%16.4%
Net marginProfit after everything, per Rs 100 of sales.10.4%10.6%11.2%14.5%
ROEProfit as a percentage of shareholders' money (from the March balance sheet).8.1%8.1%8.3%10.9%
ROCEOperating profit as a percentage of all long-term capital, owners' and lenders'.12.1%11.7%11.8%16.0%
Debt to equityBorrowings divided by shareholders' money. Lower is safer.0.11x0.09x0.07x0.00x
Interest coverHow many times operating profit covers the interest bill. Higher is safer.10.6x17.9x16.5x16.8x

Each row is coloured against this company's own usual level, not against other companies: green is better than its middle year, red worse, plain is close to it. ROE, ROCE and debt rows start once the filings carry a full balance sheet (FY22 at the earliest).

What it owns, and how that is paid for
Straight from the March balance sheet in the company's annual filing. Both bars are the whole balance sheet: what the company owns, and where the money for it came from.
as at 2026-03-31

At FY26 it owned Rs 1,492 Cr of assets. Its owners funded 83% of that and borrowings 0%.

What it owns
31%
10%
35%
11%
13%
Plant, property and projects457 Cr
Goodwill and intangibles8 Cr
Investments5 Cr
Inventory151 Cr
Owed by customers517 Cr
Cash and bank167 Cr
Everything else188 Cr
How that is paid for
83%
10%
Shareholders1,232 Cr
Borrowings3 Cr
Owed to suppliers104 Cr
Other liabilities154 Cr
Cash and equivalents
Rs 35 Cr
Net debt
Rs -34 Cr
more cash than debt
Current ratio
4.02x
short-term assets per rupee due soon
Book value / share
Rs 112
Return on assets
9.5%
EV / EBITDA
28.0x

From the March balance sheet in the company's annual filing (2026-03-31). Each bar is the full balance sheet; "everything else" is what the filed total leaves after the named lines.

Where the cash went
Profit is an accounting figure; cash flow is what actually moved. Cash from running the business, plus or minus what was spent on or received from investments, plus or minus what came from or went to lenders and shareholders, equals the change in cash.

In FY26 the business itself brought in Rs 139 Cr, spent Rs 57 Cr on plant and equipment, and cash rose by Rs 11 Cr over the year.

From running the business
+139 Cr
Spent on or received from investing
-38 Cr
From or to lenders and shareholders
-89 Cr
Net change in cash
+11 Cr
Cash from operations for every Rs 100 of profit
Rs 45
FY23
Rs 187
FY24
Rs 117
FY25
Rs 103
FY26

Rs 100 or more means every rupee of reported profit arrived as cash.

Full financial year to 2026-03-31, from the company's cash flow statement.

Against its sector
Where this stock sits within its own sector on each measure. The marker is its position in the peer group and the notch is the sector median. A position is a fact about the cohort, not a view on the stock.
Pharmaceuticals · 142
P/E49.43vs 34.93 median
Cheapest: AHCL 4.38Priciest: ORCHPHARMA 669.35
Net margin14.1%vs 10.82% median
Lowest: ZOTA -17.13%Highest: NATCOPHARM 32.85%
Revenue growth37.65%vs 17.74% median
Lowest: NECLIFE -99.99%Highest: SPARC 314.11%
Compared against
AAREYDRUGSAARTIDRUGSAARTIPHARMABBOTINDIAACCPLACUTAASAHCLAJANTPHARMAKUMSALBERTDAVDALIVUSALKEMALPAAMANTAAMBALALSAAMRUTANJANANUHPHRAPLLTDASTRAZENAUROPHARMABAJAJHCAREBALAXIBALPHARMABETABIOCONBIOFILCHEMBLUEJETBMLLBPLPHARMABROOKSCAPLIPOINTCIPLACOHANCECONCORDBIOCORONACURISDCALDIVISLABDRREDDYEMCURE

Median rather than average, so one loss-making or one very expensive peer cannot drag the reference. Valuation is shown without a colour verdict: a higher multiple can mean expensive, or faster growth expected, and only you can decide which.

Peers side by side
Every company in the same NSE industry group that we hold figures for, largest first. Tap any heading to sort by it. The same figures as the At a glance tiles, worked out the same way for every company.
Pharmaceuticals · 40 shown
Company
SUNPHARMA
Sun Pharmaceutical Industries Limited
4.19 L cr34.7x5.0x14.4%17.9%0.0520.2%+10.5%0.94%
DIVISLAB
Divi's Laboratories Limited
2.37 L cr81.2x14.2x17.4%19.0%0.0026.1%+27.8%0.34%
TORNTPHARM
Torrent Pharmaceuticals Limited
1.72 L cr76.4x9.4x11.4%-0.7612.1%+50.8%0.75%
ZYDUSLIFE
Zydus Lifesciences Limited
1.13 L cr25.2x4.2x15.5%19.2%0.4016.1%+22.0%0.98%
CIPLA
Cipla Limited
1.08 L cr32.1x3.1x9.7%14.9%0.0111.8%+2.3%1.20%
LAURUSLABS
Laurus Labs Limited
1.06 L cr97.4x20.1x20.1%19.7%0.4415.0%+29.1%0.08%
DRREDDY
Dr. Reddy's Laboratories Limited
1.03 L cr36.6x2.6x7.0%-0.158.3%-1.5%0.65%
MANKIND
Mankind Pharma Limited
91,380 cr44.8x5.6x12.5%13.7%0.3814.0%+12.9%0.05%
AUROPHARMA
Aurobindo Pharma Limited
90,436 cr24.6x2.4x9.8%13.6%0.2010.6%+16.3%0.26%
LUPIN
Lupin Limited
88,199 cr16.0x3.9x24.7%28.4%0.2618.5%+32.0%0.62%
GLENMARK
Glenmark Pharmaceuticals Limited
61,141 cr34.0x5.8x17.1%16.2%0.0010.1%+23.1%0.23%
ALKEM
Alkem Laboratories Limited
59,141 cr27.4x4.3x15.4%18.8%0.1114.6%+10.9%1.04%
BIOCON
Biocon Limited
52,718 cr95.7x1.6x1.1%2.9%0.402.4%+10.0%0.17%
IPCALAB
IPCA Laboratories Limited
49,555 cr37.8x6.2x14.4%16.4%0.0713.6%+20.8%0.11%
GLAND
Gland Pharma Limited
46,631 cr41.3x4.5x10.9%13.7%0.0216.8%+19.6%0.64%
AJANTPHARM
Ajanta Pharma Limited
41,164 cr36.2x9.1x25.1%29.4%0.0519.6%+24.8%0.85%
GLAXO
GlaxoSmithKline Pharmaceuticals Limited
40,738 cr38.1x18.0x46.8%55.4%0.0027.0%+16.6%1.75%
EMCURE
Emcure Pharmaceuticals Limited
33,581 cr33.2x6.8x20.5%25.1%0.2410.5%+22.9%0.17%
SAILIFE
Sai Life Sciences Limited
29,621 cr82.4x11.9x14.6%18.1%0.0416.1%+11.7%0.00%
WOCKPHARMA
Wockhardt Limited
29,188 cr71.5x5.9x7.8%6.5%0.4011.6%+25.9%0.00%
PPLPHARMA
Piramal Pharma Limited
25,362 cr-3.1x-3.8%0.8%0.67-3.4%+17.4%0.07%
NEULANDLAB
Neuland Laboratories Limited
24,337 cr48.6x13.0x26.6%23.1%0.1021.0%+119.2%0.06%
RUBICON
Rubicon Research Limited
23,557 cr81.1x18.3x22.4%24.3%0.2014.9%-0.00%
GRANULES
Granules India Limited
19,694 cr29.5x3.9x13.0%16.0%0.2611.8%+22.0%0.18%
COHANCE
Cohance Lifesciences Limited
17,211 cr112.2x4.4x2.6%4.8%0.043.9%-23.1%0.00%
SHILPAMED
Shilpa Medicare Limited
16,906 cr56.6x6.5x11.5%12.4%0.2517.7%+44.9%0.06%
CAPLIPOINT
Caplin Point Laboratories Limited
16,887 cr25.5x4.7x18.7%22.0%0.0029.6%+19.6%0.27%
PFIZER
Pfizer Limited
16,526 cr30.3x3.9x17.5%22.9%0.0028.6%+8.3%4.55%
ALIVUS
Alivus Life Sciences Limited
15,350 cr25.5x4.6x18.1%21.8%0.0023.3%+6.4%0.40%
ONESOURCE
Onesource Specialty Pharma Limited
15,294 cr-2.6x-0.8%0.5%0.22-3.1%+37.2%0.00%
ERIS
Eris Lifesciences Limited
15,184 cr23.3x3.9x17.1%15.7%0.5920.6%+13.0%0.00%
ASTRAZEN
AstraZeneca Pharma India Limited
14,971 cr172.4x17.1x19.4%25.5%0.007.0%+29.7%0.53%
APLLTD
Alembic Pharmaceuticals Limited
14,940 cr21.6x2.6x12.2%12.8%0.248.9%+25.7%1.45%
JUBLPHARMA
Jubilant Pharmova Limited
14,825 cr42.3x2.1x5.0%6.4%0.454.1%+17.3%0.54%
NATCOPHARM
Natco Pharma Limited
14,174 cr12.4x1.5x12.4%16.3%0.0832.9%-44.7%0.64%
MARKSANS
Marksans Pharma Limited
13,001 cr25.1x4.3x17.1%17.5%0.0116.4%+35.6%0.28%
CONCORDBIO
Concord Biotech Limited
12,860 cr47.1x6.4x13.5%16.6%0.0024.6%+26.2%0.87%
ACUTAAS
Acutaas Chemicals Limited
12,844 cr66.8x7.8x22.6%27.7%0.0226.5%+59.1%0.10%
CORONA
CORONA Remedies Limited
12,545 cr63.0x16.8x26.6%29.3%0.1913.5%-0.00%
BLISSGVS
Bliss GVS Pharma Limited
6,611 cr49.4x5.5x11.5%16.0%0.0014.1%+37.6%0.16%

Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.

The business
Sales and net profit from the company's own filings, by financial year or by quarter. Hover any bar for that period's complete figures including operating margin and the change against the comparable earlier period. The single TTM figure above is the sum of the last four quarters.
4 years · 20 quarters
Full financial years - the long arc of the business.
Sales growth
+9.3%
a year, 3 years
Profit growth
+22.2%
a year, 3 years
Operating margin
16.4%
latest year
Sales by financial yearRs 927 Cr
Net profit by financial yearRs 135 Cr
FY234 full years · hover a yearFY26

Operating margin has gone from 13.7% to 16.4% over these years - the share of every rupee of sales kept after running costs, before interest and tax. Full financial years only, so a part-year is never shown as a whole one. Hover any year for its complete figures.

Dividends paid
Cash paid per share, from the exchange's corporate-action record, restated to today's share count across bonuses and splits. Dates shown are ex-dates: you must own the shares before that date to receive the payment.
Rs 80 in 2025
Paid 5 of 6 yrs
what 2025's payouts come to on Rs 1 lakh at today's price · nothing declared in the last twelve months
What each year paid, on Rs 1 lakh
80
80
80
80
80
20
21
22
23
24
25

2025 paid Rs 0.50 per share, about Rs 80 on Rs 1 lakh at today's price. It skipped 1 of the last 6 years. Dividends are at the company's discretion and can be cut or skipped.

Large institutional deals
Bulk and block deals reported by the exchange, where a single large trade is disclosed along with the counterparty's name. Only deals above the exchange's disclosure threshold appear here.
last 5
DatePartySideQtyPriceValue
2026-09-28ANUPAM RASAYAN INDIA LIMITEDBUY22,50,000723.29Rs 162.74 Cr
2026-07-21NOVA VIDA LIMITEDBUY7,00,000485Rs 33.95 Cr
2026-07-21NOVA VIDA LIMITEDBUY7,00,000485Rs 33.95 Cr
2026-07-21ARIAN INVESTMENT LTDSELL7,00,000485Rs 33.95 Cr
2026-07-21ARIAN INVESTMENT LTDSELL7,00,000485Rs 33.95 Cr
Technical snapshot
Momentum, trend and delivery-based conviction from the actual price and volume history.
EOD 23 Oct
RSI (14) - momentum
42.4Neutral
0 oversold3070overbought 100
vs 50-DMA
-2.82%
vs 200-DMA
+57.86%
1-month
-10.26%
3-month
+34.97%
1-year
+311.81%
Realized vol (30d)
43.3%
Insider trading disclosures
Promoter, director and other insider trades in the company's own shares, as disclosed to the exchange under SEBI's insider-trading regulations - usually within a few days of the transaction.
last 18 months

Insider trading data unavailable.

Recent announcements
The company's own filings to the exchange - results, board meetings, investor calls - with a link to the source document.
last 6 months

Announcements unavailable.

Want to test a strategy on BLISSGVS?

Backtest an equity strategy on real market data, free - no card needed.

Start free

Equity price, fundamentals and realized volatility are end-of-day / quarterly from real market data. The option chain (PCR, max pain, expected move, IV, OI) is live from the exchange during market hours; outside them it shows the last session's close. Shareholding, insider trades and announcements are the company's own exchange filings. Analysis only, not investment advice.